Biotech News
New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy
-- In a randomized crossover study, sotagliflozin significantly reduced ex vivo thrombus formation from baseline under both arterial and venous flow conditions --
-- Study in living human heart tissue indicate sotagliflozin acutely and directly reduces myocardial work in hypertrophic cardiomyopathy (HCM) --
